Improved risk stratification in prevention by use of a panel of selected circulating microRNAs

[1]  Ian Graham,et al.  EUROPEAN GUIDELINES ON CARDIOVASCULAR DISEASE PREVENTION IN CLINICAL PRACTICE , 2005 .

[2]  Yi-Dong Lin,et al.  MicroRNA-34a Plays a Key Role in Cardiac Repair and Regeneration Following Myocardial Infarction. , 2015, Circulation research.

[3]  Brandon D Gallas,et al.  Comparing two correlated C indices with right‐censored survival outcome: a one‐shot nonparametric approach , 2015, Statistics in medicine.

[4]  R. Friedline,et al.  MicroRNA-378 controls classical brown fat expansion to counteract obesity , 2014, Nature Communications.

[5]  F. He,et al.  Circulating miR-208b and miR-34a Are Associated with Left Ventricular Remodeling after Acute Myocardial Infarction , 2014, International journal of molecular sciences.

[6]  M. Capogrossi,et al.  Admission levels of circulating miR-499-5p and risk of death in elderly patients after acute non-ST elevation myocardial infarction. , 2014, International journal of cardiology.

[7]  D. Francis,et al.  Mortality from ischaemic heart disease by country, region, and age: Statistics from World Health Organisation and United Nations , 2013, International journal of cardiology.

[8]  J. Smith,et al.  Circulating cardio-enriched microRNAs are associated with long-term prognosis following myocardial infarction , 2013, BMC Cardiovascular Disorders.

[9]  N. Sundaresan,et al.  A Cardiac-enriched MicroRNA, miR-378, Blocks Cardiac Hypertrophy by Targeting Ras Signaling* , 2013, The Journal of Biological Chemistry.

[10]  H. Hermeking,et al.  MicroRNA-34a regulates cardiac ageing and function , 2013, Nature.

[11]  Holger Thiele,et al.  Relation of circulating MicroRNA-133a concentrations with myocardial damage and clinical prognosis in ST-elevation myocardial infarction. , 2012, American heart journal.

[12]  M. Pencina,et al.  Interpreting incremental value of markers added to risk prediction models. , 2012, American journal of epidemiology.

[13]  M. Mayr,et al.  Prospective study on circulating MicroRNAs and risk of myocardial infarction. , 2012, Journal of the American College of Cardiology.

[14]  Shah Ebrahim,et al.  European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) , 2012, International Journal of Behavioral Medicine.

[15]  S. Silber,et al.  Circulating troponin as measured by a sensitive assay for cardiovascular risk assessment in primary prevention. , 2012, Clinical chemistry.

[16]  A. Olsson,et al.  Cost-effectiveness of rosuvastatin 20 mg for the prevention of cardiovascular morbidity and mortality: a Swedish economic evaluation of the JUPITER trial , 2012, Journal of medical economics.

[17]  J. Bauersachs,et al.  Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome. , 2011, Journal of molecular and cellular cardiology.

[18]  W. Rathmann,et al.  Cohort profile: the study of health in Pomerania. , 2011, International journal of epidemiology.

[19]  E. Olson,et al.  Pervasive roles of microRNAs in cardiovascular biology , 2011, Nature.

[20]  A. Khera,et al.  Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. , 2010, JAMA.

[21]  Michael J. Pencina,et al.  Statistical methods for assessment of added usefulness of new biomarkers , 2010, Clinical chemistry and laboratory medicine.

[22]  Jan A Staessen,et al.  Circulating MicroRNA-208b and MicroRNA-499 Reflect Myocardial Damage in Cardiovascular Disease , 2010, Circulation. Cardiovascular genetics.

[23]  T. Thum,et al.  Circulating MicroRNAs as Biomarkers and Potential Paracrine Mediators of Cardiovascular Disease , 2010, Circulation. Cardiovascular genetics.

[24]  Stefanie Dimmeler,et al.  Circulating MicroRNAs in Patients With Coronary Artery Disease , 2010, Circulation research.

[25]  S. Sharp,et al.  A simple risk score using routine data for predicting cardiovascular disease in primary care. , 2010, The British journal of general practice : the journal of the Royal College of General Practitioners.

[26]  Kunihiro Nishimura,et al.  Plasma microRNA 499 as a biomarker of acute myocardial infarction. , 2010, Clinical chemistry.

[27]  Olli Saarela,et al.  Contribution of 30 Biomarkers to 10-Year Cardiovascular Risk Estimation in 2 Population Cohorts: The MONICA, Risk, Genetics, Archiving, and Monograph (MORGAM) Biomarker Project , 2010, Circulation.

[28]  S. Cook,et al.  MicroRNA-223 regulates Glut4 expression and cardiomyocyte glucose metabolism. , 2010, Cardiovascular research.

[29]  Hugo A. Katus,et al.  MicroRNA signatures in total peripheral blood as novel biomarkers for acute myocardial infarction , 2010, Basic Research in Cardiology.

[30]  P. Libby,et al.  Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. , 2008, The New England journal of medicine.

[31]  Anders Larsson,et al.  Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. , 2008, The New England journal of medicine.

[32]  O. Kirak,et al.  Regulation of progenitor cell proliferation and granulocyte function by microRNA-223 , 2008, Nature.

[33]  M. Pencina,et al.  Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.

[34]  C. Croce,et al.  MicroRNA-133 controls cardiac hypertrophy , 2007, Nature Medicine.

[35]  Jian-Fu Chen,et al.  The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation , 2006, Nature Genetics.

[36]  P. Hildebrandt,et al.  N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. , 2005, JAMA.

[37]  S. Silber,et al.  Cardiovascular risk factors in primary care: methods and baseline prevalence rates – the DETECT program , 2005, Current medical research and opinion.

[38]  Daniel Levy,et al.  Plasma natriuretic peptide levels and the risk of cardiovascular events and death. , 2004, The New England journal of medicine.

[39]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[40]  H. Tunstall-Pedoe,et al.  Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. , 2003, European heart journal.

[41]  P. Ridker,et al.  C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. , 2000, The New England journal of medicine.

[42]  D. Levy,et al.  Prediction of coronary heart disease using risk factor categories. , 1998, Circulation.

[43]  E. DeLong,et al.  Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.